BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 23398767)

  • 21. The utility of PSA velocity in prediction of prostate cancer and high grade cancer after an initially negative prostate biopsy.
    Elshafei A; Li YH; Hatem A; Moussa AS; Ethan V; Krishnan N; Li J; Jones JS
    Prostate; 2013 Dec; 73(16):1796-802. PubMed ID: 24038200
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Twenty-year Risk of Prostate Cancer Death by Midlife Prostate-specific Antigen and a Panel of Four Kallikrein Markers in a Large Population-based Cohort of Healthy Men.
    Sjoberg DD; Vickers AJ; Assel M; Dahlin A; Poon BY; Ulmert D; Lilja H
    Eur Urol; 2018 Jun; 73(6):941-948. PubMed ID: 29519548
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Incidence of prostate cancer after termination of screening in a population-based randomised screening trial.
    Grenabo Bergdahl A; Holmberg E; Moss S; Hugosson J
    Eur Urol; 2013 Nov; 64(5):703-9. PubMed ID: 23721957
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nomogram Predicting Prostate Cancer-specific Mortality for Men with Biochemical Recurrence After Radical Prostatectomy.
    Brockman JA; Alanee S; Vickers AJ; Scardino PT; Wood DP; Kibel AS; Lin DW; Bianco FJ; Rabah DM; Klein EA; Ciezki JP; Gao T; Kattan MW; Stephenson AJ
    Eur Urol; 2015 Jun; 67(6):1160-1167. PubMed ID: 25301759
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prostate-specific antigen-based prostate cancer screening: reduction of prostate cancer mortality after correction for nonattendance and contamination in the Rotterdam section of the European Randomized Study of Screening for Prostate Cancer.
    Bokhorst LP; Bangma CH; van Leenders GJ; Lous JJ; Moss SM; Schröder FH; Roobol MJ
    Eur Urol; 2014 Feb; 65(2):329-36. PubMed ID: 23954085
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pretreatment prostate-specific antigen (PSA) velocity and doubling time are associated with outcome but neither improves prediction of outcome beyond pretreatment PSA alone in patients treated with radical prostatectomy.
    O'Brien MF; Cronin AM; Fearn PA; Smith B; Stasi J; Guillonneau B; Scardino PT; Eastham JA; Vickers AJ; Lilja H
    J Clin Oncol; 2009 Aug; 27(22):3591-7. PubMed ID: 19506163
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term Results of Active Surveillance in the Göteborg Randomized, Population-based Prostate Cancer Screening Trial.
    Godtman RA; Holmberg E; Khatami A; Pihl CG; Stranne J; Hugosson J
    Eur Urol; 2016 Nov; 70(5):760-766. PubMed ID: 27090975
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The influence of serial prostate-specific antigen (PSA) screening on the PSA velocity at diagnosis.
    Martin NE; Chen MH; Catalona WJ; Loeb S; Roehl KA; D'Amico AV
    Cancer; 2008 Aug; 113(4):717-22. PubMed ID: 18615505
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Association between Prostate-Specific Antigen Velocity (PSAV), Value and Acceleration, and of the Free PSA/Total PSA Index or Ratio, with Prostate Conditions.
    Flores-Fraile MC; Padilla-Fernández BY; Valverde-Martínez S; Marquez-Sanchez M; García-Cenador MB; Lorenzo-Gómez MF; Flores-Fraile J
    J Clin Med; 2020 Oct; 9(11):. PubMed ID: 33114134
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Usefulness of prostate-specific antigen velocity in screening for prostate cancer.
    Ito K; Yamamoto T; Ohi M; Kubota Y; Fukabori Y; Kurokawa K; Suzuki K; Yamanaka H
    Int J Urol; 2002 Jun; 9(6):316-21. PubMed ID: 12110095
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pretreatment PSA velocity and risk of death from prostate cancer following external beam radiation therapy.
    D'Amico AV; Renshaw AA; Sussman B; Chen MH
    JAMA; 2005 Jul; 294(4):440-7. PubMed ID: 16046650
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ejaculation Frequency and Risk of Prostate Cancer: Updated Results with an Additional Decade of Follow-up.
    Rider JR; Wilson KM; Sinnott JA; Kelly RS; Mucci LA; Giovannucci EL
    Eur Urol; 2016 Dec; 70(6):974-982. PubMed ID: 27033442
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prostate-specific antigen velocity versus prostate-specific antigen doubling time for prediction of 11C choline PET/CT in prostate cancer patients with biochemical failure after radical prostatectomy.
    Giovacchini G; Picchio M; Parra RG; Briganti A; Gianolli L; Montorsi F; Messa C
    Clin Nucl Med; 2012 Apr; 37(4):325-31. PubMed ID: 22391699
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Optimal timing, cutoff, and method of calculation of preoperative prostate-specific antigen velocity to predict relapse after prostatectomy: a report from SEARCH.
    King CR; Freedland SJ; Terris MK; Aronson WJ; Kane CJ; Amling CL; Presti JC
    Urology; 2007 Apr; 69(4):732-7. PubMed ID: 17445660
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Distinct prognostic role of prostate-specific antigen doubling time and velocity at emergence of androgen independence in patients treated with chemotherapy.
    Daskivich TJ; Regan MM; Oh WK
    Urology; 2007 Sep; 70(3):527-31. PubMed ID: 17905110
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Outcome following active surveillance of men with screen-detected prostate cancer. Results from the Göteborg randomised population-based prostate cancer screening trial.
    Godtman RA; Holmberg E; Khatami A; Stranne J; Hugosson J
    Eur Urol; 2013 Jan; 63(1):101-7. PubMed ID: 22980443
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of prediagnostic prostate-specific antigen dynamics as predictors of death from prostate cancer in patients treated conservatively.
    O'Brien MF; Cronin AM; Fearn PA; Savage CJ; Smith B; Stasi J; Scardino PT; Fisher G; Cuzick J; Møller H; Oliver RT; Berney DM; Foster CS; Eastham JA; Vickers AJ; Lilja H;
    Int J Cancer; 2011 May; 128(10):2373-81. PubMed ID: 20658531
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of obesity on the utility of preoperative prostate-specific antigen velocity to predict for relapse after prostatectomy: a report from the SEARCH database.
    King CR; Freedland SJ; Terris MK; Kane CJ; Amling CL; Aronson WJ; Presti JC
    Urology; 2007 May; 69(5):921-6. PubMed ID: 17482935
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Significance of preoperative PSA velocity in men with low serum PSA and normal DRE.
    Makarov DV; Loeb S; Magheli A; Zhao K; Humphreys E; Gonzalgo ML; Partin AW; Han M
    World J Urol; 2011 Feb; 29(1):11-4. PubMed ID: 21153643
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Association of Radical Local Treatment with Mortality in Men with Very High-risk Prostate Cancer: A Semiecologic, Nationwide, Population-based Study.
    Stattin P; Sandin F; Thomsen FB; Garmo H; Robinson D; Lissbrant IF; Jonsson H; Bratt O
    Eur Urol; 2017 Jul; 72(1):125-134. PubMed ID: 27481175
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.